Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed
Abstract Background Novel anticoagulations (NOACs) are increasingly prescribed for the prevention of stroke in premenopausal women with atrial fibrillation. Small studies suggest NOACs are associated with a higher risk of abnormal uterine bleeds than vitamin K antagonists (VKAs). Because there is no...
Main Authors: | Herbert J. A. Rolden, Angela H. E. M. Maas, Gert Jan van der Wilt, Janneke P. C. Grutters |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-017-0692-1 |
Similar Items
-
Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
by: S. G. Kanorskii
Published: (2016-09-01) -
The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01) -
RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01) -
Rivaroxaban in non valvular atrial fibrillation: subgroups analysis
by: Cesare Greco
Published: (2015-08-01) -
Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019-05-01)